NEXGEL, INC. (NXGL) Form 8-K — Aug 17, 2026

$NXGLForm 8-KItems 2.02, 9.01Filed Aug 17, 2026, 8:15 AM ET0001493152-26-038637Original filing

NexGel reported second quarter 2026 revenue of $3.69 million with a net loss of $2.87 million, a figure that included $756,554 of BioNX intangible amortization, $273,710 of one-time transaction expenses, and a $144,495 charge from recalling all SilverSeal inventory from Amazon ahead of an August hospital launch. The company said integration of the Celularity transaction and the BioNX Surgical rollout has progressed more slowly than anticipated, with ongoing supply chain constraints leaving a BioNX Surgical backlog of approximately $795,000.

Key figures

Revenue: 3690000
Bio NX surgical backlog: 795000
Bio NX intangible amortization: 756554
One time transaction expenses: 273710
Silverseal amazon recall charge: 144495
Atw restricted cash released post quarter: 710000

Price after filing

1 day: +2.4%7 days: +1.2%30 days: -33.9%

Close on the filing date to close N calendar days later (from $0.38). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.